Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Autologous bone marrow-derived mononuclear cell therapy in three patients with severe asthma

Tytuł:
Autologous bone marrow-derived mononuclear cell therapy in three patients with severe asthma
Autorzy:
Fabio S. Aguiar
André S. Melo
Ana Maria S. Araújo
Alexandre P. Cardoso
Sergio Augusto L. de Souza
Miquéias Lopes-Pacheco
Fernanda F. Cruz
Debora G. Xisto
Karina D. Asensi
Lanuza Faccioli
Anna Beatriz S. Salgado
Maria Carolina P. P. Landesmann
Regina C. S. Goldenberg
Bianca Gutfilen
Marcelo M. Morales
Patricia R. M. Rocco
Jose R. Lapa e Silva
Temat:
Asthma
Bone marrow mononuclear cells
Cell therapy
Autologous transplantation
Lung
Medicine (General)
R5-920
Biochemistry
QD415-436
Źródło:
Stem Cell Research & Therapy, Vol 11, Iss 1, Pp 1-9 (2020)
Wydawca:
BMC, 2020.
Rok publikacji:
2020
Kolekcja:
LCC:Medicine (General)
LCC:Biochemistry
Typ dokumentu:
article
Opis pliku:
electronic resource
Język:
English
ISSN:
1757-6512
Relacje:
http://link.springer.com/article/10.1186/s13287-020-01675-x; https://doaj.org/toc/1757-6512
DOI:
10.1186/s13287-020-01675-x
Dostęp URL:
https://doaj.org/article/625d3159a0524f6e83bf88b351fd567d  Link otwiera się w nowym oknie
Numer akcesji:
edsdoj.625d3159a0524f6e83bf88b351fd567d
Czasopismo naukowe
Abstract Background Despite recent advances in understanding its pathophysiology and development of novel therapies, asthma remains a serious public health issue worldwide. Combination therapy with inhaled corticosteroids and long-acting β2-adrenoceptor agonists results in disease control for many patients, but those who exhibit severe asthma are often unresponsive to conventional treatment, experiencing worse quality of life, frequent exacerbations, and increasing healthcare costs. Bone marrow-derived mononuclear cell (BMMC) transplantation has been shown to reduce airway inflammation and remodeling and improve lung function in experimental models of allergic asthma. Methods This is a case series of three patients who presented severe asthma, unresponsive to conventional therapy and omalizumab. They received a single intravenous dose of autologous BMMCs (2 × 107) and were periodically evaluated for 1 year after the procedure. Endpoint assessments included physical examination, quality of life questionnaires, imaging (computed tomography, single-photon emission computed tomography, and ventilation/perfusion scan), lung function tests, and a 6-min walk test. Results All patients completed the follow-up protocol. No serious adverse events attributable to BMMC transplantation were observed during or after the procedure. Lung function remained stable throughout. A slight increase in ventilation of the right lung was observed on day 120 after BMMC transplantation in one patient. All three patients reported improvement in quality of life in the early post-procedure course. Conclusions This paper described for the first time the effects of BMMC therapy in patients with severe asthma, providing a basis for subsequent trials to assess the efficacy of this therapy.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies